(UHZ-ith-row-MY-sin)
Indicates Canadian trade names.
Action:
Interferes with microbial protein synthesis.
Indications:
Adults:
Treatment of infections of the respiratory tract, chronic obstructive pulmonary disease (COPD), community acquired pneumonia,
Children:
Treatment of acute otitis media caused by susceptible organisms; community-acquired pneumonia, treatment of pharyngitis/tonsillitis caused by
Contraindications:
Hypersensitivity to azithromycin, erythromycin, or to any macrolide antibiotic.
Acute Otitis Media
Children:
Bacterial Infections
Adults:
Community Acquired Pneumonia
Adults:
Children Gonorrhea
Adults:
Mild to Moderate COPD
Adults:
Adults:
Pelvic Inflammatory Disease
Adults:
Pharyngitis/Tonsillitis
Adults:
Children:
STDs
Adults:
Uncomplicated Skin and Skin Structure Infections
Adults:
Route/Dosage:
PO
10 mg/kg as a single dose on the first day, not to exceed 500 mg/day. Then give 5 mg/kg on days 2 through 5, not to exceed 250 mg/day.
PO
500 mg as single dose on first day, then 250 mg/day on days 2 through 5.
PO
500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5.
IV
500 mg as a single daily dose for
2 days. Follow IV therapy by the oral route at a single daily dose of 500 mg to complete 7- to 10-day course of therapy.
6 mo:
PO
10 mg/kg as a single dose on the first day (not to exceed 500 mg/day), followed by 5 mg/kg on days 2 through 5 (not to exceed 250 mg/day).
PO
Single 2 g dose.
PO
500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5.
PO
1.2 g taken once weekly.
IV
500 mg as a single daily dose for 1 to 2 days. Follow IV therapy by the oral route at a single daily dose of 250 mg to complete a 7-day course of therapy.
PO
500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5.
PO
12 mg/kg/day for 5 days, not to exceed 500 mg/day.
PO
Single 1 g dose.
PO
500 mg as a single dose on the first day followed by 250 mg once daily for 4 days.
Interactions:
HMG-CoA reductase inhibitors (eg, lovastatin): Increased risk of myopathy and rhabdomyolysis.
Tacrolimus: Increased tacrolimus plasma levels with increased risk of toxicity.
Warfarin: The anticoagulant effect may be increased, increasing the risk of hemorrhage.
Lab Test Interferences:
None well documented.
Adverse Reactions:
Precautions:
Pregnancy: Category B.
Lactation: Undetermined.
Cardiac effects: Serious cardiovascular events have occurred with other macrolide antibiotics, especially when given concomitantly with certain antihistamines (eg, terfenadine, astemizole).
Gonorrhea/Syphilis: Ineffective for treatment of these infections.
Hepatic/Renal impairment: Use cautiously.
Pneumonia: Only effective for mild community-acquired pneumonia.
Pseudomembranous colitis: May be factor in patients who develop diarrhea.
Administration/Storage:
Oral Suspension
Injection
Assessment/Interventions:
Patient/Family Education:
AtoZ Drug Facts · Copyright©2000 by Facts and Comparisons